| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $45,616 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Pamir Ozan | Chief Financial Officer | 1 | $45,616 | 0 | $0 | $45,616 |
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and …
Over the last 12 months, insiders at Niagen Bioscience Inc have bought $45,616 and sold $0 worth of Niagen Bioscience Inc stock.
On average, over the past 5 years, insiders at Niagen Bioscience Inc have bought $45,616 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Pamir Ozan (Chief Financial Officer) — $45,616.
The last purchase of 6,685 shares for transaction amount of $45,616 was made by Pamir Ozan (Chief Financial Officer) on 2025‑11‑14.
| 2025-11-14 | Pamir Ozan | Chief Financial Officer | 6,685.4 0.0087% | $6.82 | $45,616 | -43.81% |
| Increased Positions | 96 | +52.17% | 5M | +14.27% |
| Decreased Positions | 82 | -44.57% | 4M | -13.14% |
| New Positions | 34 | New | 902,912 | New |
| Sold Out Positions | 30 | Sold Out | 2M | Sold Out |
| Total Postitions | 198 | +7.61% | 32M | +1.13% |